Sponsor pipeline

Genmab clinical trial pipeline

Get alerts when Genmab's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

10 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 6 with minor changes only.

  1. Notable

    Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

    Start date pushed from Sep 15, 2026 to Oct 15, 2026

    Also in this update: Trial sites expanded: 1 → 4 locations; and 1 more change in the last 30 days

    GenmabPhase 3 NCT07775287 Registry history of NCT07775287 on ClinicalTrials.gov (opens the registry)

Show 6 trials with minor changes only
  1. Minor

    RAINFOL-02 · Rina-S Compared to Treatment of Investigator's Choice · Platinum Resistant Ovarian Cancer

    Final enrollment: 584 participants (planned 530)

    Also in this update: Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026; Study completion moved earlier from May 23, 2028 to Oct 2027

    GenmabPhase 3 NCT06619236 Registry history of NCT06619236 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-05 NCT07859215 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… Phase 3 Not Yet Recruiting

Active trials by phase

Phase 1
6
Phase 1/2
7
Phase 2
4
Phase 3
15

Disease areas by active trials, top 10 of 21

Get alerts when Genmab's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free